Fortress Biotech Corp (FBIO) Net Margin

Fortress Biotech Inc - graphic logo of issuer FBIO

Fortress Biotech, Inc. (FBIO) relies on the diversification of its subsidiaries to ensure the stable development of its assets. High barriers to entry have been established through the acquisition of early-stage oncology patents under strict FDA supervision. The net margin time series confirms the effectiveness of this model, where the value of 131.20 serves as the current metric. A unified IT system for procurement and logistics management guarantees operational continuity.

Fortress Biotech, Inc. (FBIO) - Return on Sales by Net Profit from 07/04/2022 to 11/19/2026

Financial and market metric breakdowns for Fortress Biotech Corp (FBIO)

- market value and analyst target forecast:
Comprehensive company analysis:fortressbiotech.com - FBIO
Manufactured product of Fortress

Net profit margin determines the share of profit remaining with the business after covering all operating and tax expenses. This metric measures the conversion of revenue into actual income, reflecting the fundamental efficiency of capital management. By analyzing the net profit margin, an investor assesses the model's resilience to market shocks. For Fortress Biotech, Inc. (FBIO), the volatility of this metric is driven by logistical disruptions in the supply of components for oncology drugs. Geopolitical instability directly restricts distribution, reducing the profitability of each product sold.